SEC Filing Details

Document Details

Form

DEFA14A

Filing Date

May 17, 2022

Document Date

May 17, 2022

Form Description

Additional proxy soliciting materials - definitive

Filing Group

Proxy Filings

Company

Coeptis Therapeutics Holdings, Inc.

Issuer

COEPTIS THERAPEUTICS INC.

Filing Formats

View HTML

Download PDF

Download DOC

Download XLS

Coeptis Therapeutics Holdings, Inc.

This section of our website may contain dated or archived information which should not be considered current and may no longer be accurate. For current information, you are encouraged to review our most recent official corporate documents on file with the U.S. Securities and Exchange Commission. The statements that are not historical facts contained in releases or in our posted events and presentations are forward-looking statements that involve risks and uncertainties, including, but not limited to, the results of research and development efforts, the results of preclinical and clinical testing, the effect of regulation by the FDA and other agencies, the impact of competitive products, product development, commercialization and technological difficulties, and other risks detailed in the company’s Securities and Exchange Commission filings. Coeptis Therapeutics Holdings, Inc. does not undertake any obligation to update forward-looking statements after the date of such releases except to the extent required under applicable federal and state securities laws. This website contains links to websites maintained by other companies. Coeptis Therapeutics is providing these links to readers only as a convenience. The inclusion of any link does not imply that Coeptis Therapeutics endorses any third-party website or third-party company or product. Coeptis Therapeutics does not have any control over the content of such third-party websites and assumes no responsibility whatsoever for the functionality of such websites or for the accuracy of any information presented at such other websites.